• Consensus Rating: Buy
  • Consensus Price Target: $15.25
  • Forecasted Upside: 93.28 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.05 (0.64%)

This chart shows the closing price for ZYME by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Zymeworks Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ZYME and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZYME

Analyst Price Target is $15.25
▲ +93.28% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Zymeworks in the last 3 months. The average price target is $15.25, with a high forecast of $27.00 and a low forecast of $8.00. The average price target represents a 93.28% upside from the last price of $7.89.

This chart shows the closing price for ZYME for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 8 polled investment analysts is to buy stock in Zymeworks. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/21/2022HC WainwrightBoost TargetNeutral$8.00 ➝ $10.00Low
11/1/2022HC WainwrightDowngradeBuy ➝ Neutral$40.00 ➝ $8.00Low
10/24/2022Stifel NicolausLower TargetBuy$21.00 ➝ $18.00Low
10/21/2022SVB LeerinkDowngradeOutperform ➝ Market Perform$19.00 ➝ $8.00Low
10/4/2022Wells Fargo & CompanyLower TargetOverweight$45.00 ➝ $9.00Low
9/14/2022CitigroupLower Target$27.00 ➝ $21.00Low
8/29/2022CitigroupLower TargetBuy$28.00 ➝ $27.00Low
5/27/2022SVB LeerinkBoost TargetOutperform$18.00 ➝ $19.00Medium
5/23/2022HC WainwrightLower TargetBuy$44.00 ➝ $40.00Medium
5/5/2022GuggenheimUpgradeNeutral ➝ Buy$14.00Medium
3/15/2022Evercore ISIInitiated CoverageOutperform$15.00High
2/28/2022CitigroupLower Target$53.00 ➝ $30.00Low
2/9/2022Wells Fargo & CompanyLower TargetOverweight$56.00 ➝ $48.00Medium
2/1/2022Raymond JamesLower TargetOutperform$50.00 ➝ $27.00High
1/20/2022Raymond JamesLower TargetOutperform$74.00 ➝ $62.00High
1/6/2022Raymond JamesReiterated RatingOutperform$74.00High
12/10/2021SVB LeerinkUpgradeMarket Perform ➝ OutperformLow
12/9/2021Raymond JamesDowngradeStrong-Buy ➝ Outperform$74.00Low
11/15/2021SVB LeerinkReiterated RatingHold$43.00High
11/10/2021SVB LeerinkLower TargetMarket Perform$28.00 ➝ $27.00High
11/4/2021Raymond JamesSet TargetStrong-Buy$74.00Low
11/4/2021SVB LeerinkLower TargetMarket Perform$43.00 ➝ $28.00Medium
10/6/2021Jefferies Financial GroupInitiated CoverageHold$32.00High
9/30/2021Wells Fargo & CompanyReiterated RatingBuy$56.00High
9/20/2021HC WainwrightReiterated RatingBuy$44.00Low
9/13/2021Raymond JamesSet TargetStrong-Buy$74.00Medium
8/6/2021Raymond JamesReiterated RatingStrong-Buy$74.00Medium
8/5/2021HC WainwrightLower TargetBuy$55.00 ➝ $44.00High
5/7/2021HC WainwrightLower TargetBuy$57.00 ➝ $55.00High
5/6/2021Raymond JamesSet TargetStrong-Buy$74.00Medium
3/30/2021Credit Suisse GroupInitiated CoverageOutperform$55.00High
3/3/2021Raymond JamesSet TargetStrong-Buy$74.00Medium
3/3/2021SVB LeerinkReiterated RatingOutperform ➝ Market Perform$50.00 ➝ $41.00High
2/25/2021Raymond JamesSet TargetStrong-Buy$74.00High
2/25/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$50.00 ➝ $41.00High
2/8/2021HC WainwrightReiterated RatingBuy$57.00Low
2/3/2021Raymond JamesSet TargetStrong-Buy$74.00Low
1/29/2021CitigroupUpgradeNeutral ➝ BuyLow
1/28/2021Wells Fargo & CompanyLower Target$71.00 ➝ $56.00Low
1/28/2021Raymond JamesSet TargetStrong-Buy$74.00Low
1/28/2021SVB LeerinkLower TargetOutperform$66.00 ➝ $50.00Low
1/28/2021BarclaysLower TargetEqual Weight$47.00 ➝ $38.00High
1/25/2021CitigroupDowngradeBuy ➝ Neutral$50.00 ➝ $53.00High
1/19/2021Raymond JamesBoost TargetStrong-Buy$60.00 ➝ $74.00Medium
1/12/2021Raymond JamesSet TargetStrong-Buy$60.00High
1/12/2021Wells Fargo & CompanyBoost TargetOverweight$58.00 ➝ $71.00High
1/12/2021SVB LeerinkBoost TargetOutperform$45.00 ➝ $66.00High
12/2/2020Raymond JamesSet TargetStrong-Buy$60.00Low
11/17/2020Raymond JamesSet TargetStrong-Buy$60.00High
11/4/2020Raymond JamesSet TargetStrong-Buy$60.00High
10/26/2020Raymond JamesSet TargetStrong-Buy$60.00Low
9/29/2020JPMorgan Chase & Co.Initiated CoverageNeutralLow
8/6/2020Raymond JamesSet TargetStrong-Buy$60.00Medium
8/6/2020SVB LeerinkInitiated CoverageOutperform$45.00Medium
7/16/2020Raymond JamesSet TargetStrong-Buy$60.00Low
7/14/2020GuggenheimLower Target$54.00 ➝ $48.00Low
7/9/2020Raymond JamesSet TargetStrong-Buy$60.00Medium
7/9/2020HC WainwrightLower TargetBuy$60.00 ➝ $54.00Medium
6/14/2020Bloom BurtonReiterated RatingBuyLow
6/3/2020Raymond JamesSet TargetStrong-Buy$60.00Low
6/2/2020CitigroupBoost TargetBuy$49.00 ➝ $50.00High
5/8/2020Paradigm CapitalReiterated RatingBuy$51.00Medium
5/8/2020Raymond JamesSet TargetStrong-Buy$60.00High
5/8/2020HC WainwrightReiterated RatingBuy$60.00High
4/2/2020Raymond JamesSet TargetStrong-Buy$60.00Low
3/3/2020HC WainwrightReiterated RatingBuy$65.00 ➝ $60.00High
2/20/2020HC WainwrightReiterated RatingBuy$65.00Low
2/3/2020Stifel NicolausBoost TargetBuy$45.00 ➝ $70.00Medium
1/15/2020Wells Fargo & CompanyReiterated RatingOverweight$48.00 ➝ $58.00Low
1/14/2020Raymond JamesReiterated RatingBuy$60.00Low
1/10/2020Wolfe ResearchInitiated CoverageOutperform$61.00High
12/9/2019JPMorgan Chase & Co.Initiated CoverageNeutral$43.00High
11/27/2019GuggenheimInitiated CoverageBuy$48.00Low
11/25/2019Raymond JamesBoost TargetStrong-Buy$40.00 ➝ $60.00Low
11/25/2019HC WainwrightInitiated CoverageBuy$65.00High
11/21/2019Stifel NicolausReiterated RatingBuyHigh
11/19/2019GuggenheimInitiated CoverageBuy$48.00Medium
11/7/2019Raymond JamesSet TargetStrong-Buy$40.00High
10/29/2019Raymond JamesSet TargetStrong-Buy$40.00Low
10/17/2019Raymond JamesReiterated RatingStrong-Buy$40.00Low
9/30/2019Raymond JamesUpgradeOutperform ➝ Strong-Buy$36.00 ➝ $40.00High
9/27/2019Raymond JamesSet TargetOutperform$36.00High
8/30/2019Stifel NicolausInitiated CoverageBuy$45.00High
8/27/2019CitigroupBoost TargetBuy$22.00 ➝ $49.00Medium
8/7/2019Raymond JamesSet TargetOutperform$36.00Low
8/5/2019BarclaysBoost TargetEqual Weight$15.00 ➝ $23.00Medium
7/31/2019Raymond JamesSet TargetOutperform$36.00Medium
7/18/2019Raymond JamesReiterated RatingOutperform$36.00Low
7/18/2019Deutsche Bank AktiengesellschaftInitiated CoverageBuy ➝ Buy$34.00Medium
5/30/2019Raymond JamesReiterated RatingOutperform$36.00High
5/15/2019Raymond JamesSet TargetOutperform$36.00Low
5/3/2019Raymond JamesSet TargetOutperform$36.00Low
4/26/2019Raymond JamesBoost TargetOutperform$29.00 ➝ $36.00Low
4/22/2019Wells Fargo & CompanyBoost TargetOutperform$37.00 ➝ $42.00Low
3/14/2019Raymond JamesSet TargetOutperform$29.00Medium
3/8/2019Raymond JamesReiterated RatingOutperform$29.00Low
12/10/2018Raymond JamesSet TargetOutperform$29.00Medium
11/28/2018Raymond JamesBoost TargetOutperform$27.00 ➝ $29.00High
10/15/2018Raymond JamesSet TargetOutperform$27.00Low
9/5/2018Raymond JamesSet TargetBuy$27.00Low
8/15/2018Raymond JamesReiterated RatingBuy$27.00Low
8/2/2018CitigroupUpgradeNeutral ➝ Buy$19.00High
6/21/2018CitigroupLower TargetNeutral ➝ Neutral$20.00 ➝ $19.00Low
6/6/2018CitigroupDowngradeBuy ➝ NeutralHigh
6/5/2018Raymond JamesBoost TargetOutperform ➝ Outperform$22.00 ➝ $27.00Medium
6/4/2018Wells Fargo & CompanyBoost TargetOutperform ➝ Outperform$20.00 ➝ $37.00Medium
5/18/2018Raymond JamesBoost TargetOutperform$18.00 ➝ $22.00Low
5/14/2018LADENBURG THALM/SH SHInitiated CoverageBuy$25.00Low
5/11/2018BarclaysUpgradeUnderweight ➝ Equal Weight$8.00 ➝ $15.00High
3/19/2018Raymond JamesInitiated CoverageOutperform ➝ Outperform$18.00Low
(Data available from 11/28/2017 forward)

News Sentiment Rating

0.35 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 3 very negative mentions
  • 3 very positive mentions
  • 14 positive mentions
  • 4 negative mentions
  • 5 very negative mentions
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
  • 5 very positive mentions
  • 19 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
  • 2 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 2 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Zymeworks logo
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It is also advancing a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
Read More

Today's Range

Now: $7.89
Low: $7.80
High: $8.15

50 Day Range

MA: $6.62
Low: $4.89
High: $8.49

52 Week Range

Now: $7.89
Low: $4.11
High: $21.44


14,857 shs

Average Volume

1,245,133 shs

Market Capitalization

$497.04 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Zymeworks?

The following Wall Street research analysts have issued reports on Zymeworks in the last year: Citigroup Inc., Evercore ISI, Guggenheim, HC Wainwright, Raymond James, Stifel Nicolaus, SVB Leerink LLC, and Wells Fargo & Company.
View the latest analyst ratings for ZYME.

What is the current price target for Zymeworks?

8 Wall Street analysts have set twelve-month price targets for Zymeworks in the last year. Their average twelve-month price target is $15.25, suggesting a possible upside of 93.3%. Raymond James has the highest price target set, predicting ZYME will reach $27.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $8.00 for Zymeworks in the next year.
View the latest price targets for ZYME.

What is the current consensus analyst rating for Zymeworks?

Zymeworks currently has 2 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ZYME will outperform the market and that investors should add to their positions of Zymeworks.
View the latest ratings for ZYME.

What other companies compete with Zymeworks?

How do I contact Zymeworks' investor relations team?

Zymeworks' physical mailing address is 1385 WEST 8TH AVENUE SUITE 540, VANCOUVER A1, V6H 3V9. The company's listed phone number is (604) 678-1388 and its investor relations email address is [email protected] The official website for Zymeworks is www.zymeworks.com. Learn More about contacing Zymeworks investor relations.